There’s something particularly ironic about a country many consider to be “behind the times” whipping an advanced cancer treatment out of it’s back pocket.
MIAMI (PRWEB) July 21, 2015
Regenestem Network Mexico, has announced plans to make CimaVax, a vaccine treatment for lung cancer, available to patients through Regenestem Clinics in Mexico. Developed 2011 to treat non small cell lung cancer, CimaVax, is not a cure for lung cancer, but a vaccine that essentially slows the growth process of a tumor.
According to the American Lung Association, lung cancer kills more people in the U.S. than prostate, breast and colorectal cancer combined, and survival rates are bleak. Lung cancers are hard to catch early, and more than half of all lung cancer patients die within one year of diagnosis.
CimaVax works by helping the patient’s immune system create antibodies to fight against a protein that causes cancerous cells to grow, thus slowing the tumor's progress. CimaVax is inexpensive to make and far less toxic than chemotherapy, according to HCMI researchers, who also found that it improved patients’ quality of life by reducing symptoms such as coughing and breathlessness.
Several European countries as well as Japan have already begun clinical trials using CimaVax, and the U.S. may not be far behind. In June of this year, Buffalo, N.Y.-based Roswell Park Cancer Institute struck a deal with a Cuban biotechnology institute to import and conduct clinical trials on a vaccine for lung cancer. Scientists at Roswell think CimaVax could help prevent lung cancer in the future, and Roswell CEO Candace Johnson hopes to get U.S. Food and Drug Administration approval to begin clinical trials within a year.
However, Regenestem, Mexico is making sure no one has to wait to receive the CimaVax vaccine.
Clinical trials of CimaVax have been conducted in Cuba since 2008, and the vaccine has been used to treat cancer patients there since 2011.
For more than 50 years, the U.S. trade embargo prevented Cuba from accessing U.S. medicines and supplies; during that time, the Cuban government made biotech research and medical innovation among the country’s top priorities, building a model public health system with more than twice the number of doctors per capita as the U.S., while maintaining the same life expectancy as the U.S.
Today, Cuba’s biotech industry owns about 1,200 international patents and sells medicine and equipment to more than 50 countries, according to the World Health Organization. Cuba has created vaccines for meningitis B and hepatitis B, and has developed promising drugs to help treat tumors in the head, neck and brain.
For more information on CimaVax lung cancer vaccine, visit http://www.cimavaxvaccines.com. For more information about Regenestem Network, visit Regenestem Website, email firstname.lastname@example.org, or call 305-224-1858.
Regenestem Network, a division of the Global Stem Cells Group, Inc., is an international medical practice association committed to researching and producing comprehensive stem cell treatments for patients worldwide. Having assembled a highly qualified staff of medical specialists—professionals trained in the latest cutting-edge techniques in cellular medicine—Regenestem continues to be a leader in delivering the latest protocols in the adult stem cell arena. Global Stem Cells Group and Regenestem Network are expanding the company’s clinical presence worldwide by partnering with experienced and qualified regenerative medicine physicians to open new clinics licensed and developed under the Regenestem banner. In 2014, Global Stem Cells Group expanded the Regenestem Network’s global presence to 20 countries.
Regenestem offers stem cell treatments to help treat a variety of diseases and conditions including arthritis, autism, chronic obstructive pulmonary disease (COPD), diabetes, and pain due to injuries at various facilities worldwide. Regenestem Oaxaca will have an international staff experienced in administering the latest in cellular therapies.
Regenestem is certified for the medical tourism market, and staff physicians are board-certified or board-eligible. Regenestem clinics provide services in more than 10 specialties, attracting patients from the United States and around the world.